Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)

Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People

NCT00028366 ·Status: COMPLETED ·Phase: NA

Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjects

NCT00144833 ·Status: TERMINATED ·Phase: PHASE3

Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2)

NCT00144170 ·Status: COMPLETED ·Phase: PHASE3

A Comparison of Atazanavir and Nelfinavir, Each in Combination With 2 NRTIs, in Patients Who Have Failed Treatments Without a Protease Inhibitor

NCT00028067 ·Status: TERMINATED ·Phase: PHASE3

Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure

NCT00025727 ·Status: UNKNOWN ·Phase: PHASE3

A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID in Comparison to 400 mg Lopinavir (LPV) Plus 100 mg RTV p.o. BID in Combination With Standard Background Regimen in ARV Therapy naïve Patients.

NCT00144105 ·Status: TERMINATED ·Phase: PHASE2

Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r

NCT00756730 ·Status: COMPLETED ·Phase: PHASE4

A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment

NCT01448707 ·Status: COMPLETED ·Phase: PHASE3

Atazanavir/Ritonavir Maintenance Therapy

NCT00084019 ·Status: COMPLETED ·Phase: NA

Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART

NCT00038532 ·Status: COMPLETED ·Phase: PHASE2

Pharmacokinetic Study of Two HIV Protease Inhibitors in Patients

NCT00420355 ·Status: TERMINATED ·Phase: PHASE4

Study to Evaluate the Activity and Tolerability of Lopinavir/Ritonavir and Lamivudine Bitherapy in HIV Patients With Viral Suppression

NCT01471821 ·Status: COMPLETED ·Phase: PHASE4

Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC

NCT01620944 ·Status: TERMINATED ·Phase: PHASE3

A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen

NCT00931463 ·Status: COMPLETED ·Phase: PHASE4

ABT-378/Ritonavir and Efavirenz in HIV-Infected Patients Who Have Taken More Than One Protease Inhibitor in the Past

NCT00004582 ·Status: COMPLETED ·Phase: PHASE2

Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women

NCT00326716 ·Status: COMPLETED ·Phase: PHASE1

Effect of the Atazanavir (ATV) 150L Mutation on Subsequent Treatment Response in HIV Infected Subjects

NCT00096746 ·Status: COMPLETED

Dose Finding Confirmation of Atazanavir With Ritonavir and Efavirenz (ATV/RTV + EFV) in Healthy Subjects

NCT00357188 ·Status: COMPLETED ·Phase: PHASE1

Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir/Ritonavir on Cardiovascular Disease Risk Factors

NCT00720590 ·Status: COMPLETED ·Phase: NA

Comparison of Treatment Simplification by LPV/r vs Current Treatment Continuation in HIV-Infected Patients

NCT00140751 ·Status: COMPLETED ·Phase: PHASE3

A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors

NCT00004580 ·Status: COMPLETED ·Phase: PHASE1

Nevirapine or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir in Human Immunodeficiency Virus (HIV)-1-infected Treatment Naive Adults

NCT00389207 ·Status: COMPLETED ·Phase: PHASE3

Treatment Simplification by Darunavir/Ritonavir 800/100 mg Once a Day Versus a Triple Combination Therapy With Darunavir/Ritonavir

NCT00458302 ·Status: COMPLETED ·Phase: PHASE3

Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients

NCT01332227 ·Status: COMPLETED ·Phase: PHASE4

Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug Resistance

NCT00046033 ·Status: COMPLETED ·Phase: PHASE2